T. Rowe Price Reports 16.6% Passive Stake In Beta Bionics, 13G Shows
The filing lists 8,943,061 shares, with a health sciences fund holding a slice, as a securities class action against the company is pending.
T. Rowe Price Associates holds 8,943,061 shares of Beta Bionics, or 16.6% of the common stock, according to a Schedule 13G passive ownership disclosure filed Wednesday. The event date in the filing is September 30.
What the 13G says
The filing lists sole voting power over 8,939,271 shares and no shared voting power. T. Rowe Price is classed as an investment adviser.
It certifies the shares were bought and are held in the ordinary course of business, not to change or influence control of Beta Bionics. The firm also says the filing is not an admission that it is the beneficial owner of the shares, and it expressly denies beneficial ownership.
T. Rowe Price Health Sciences Fund, which the firm advises, has an interest in 2,408,699 of the shares. The filing puts that at 5.4% of the class. The filing adds that its clients hold the right to receive dividends and sale proceeds, and that not more than 5% of the class is owned by any one client, except as may be indicated in a joint filing with one of its funds.
The lawsuit behind the stock
Beta Bionics, which sells the iLet automated insulin pump, is the target of a securities class action covering investors who bought shares between July 30, 2025 and February 24, 2026. The complaint alleges the company concealed thousands of device complaints, and says the FDA published a warning letter on February 24.
The class action allegations cite an FDA Form 483 from June 2025 that identified 18,000 unreported iLet complaints. The stock fell 37% after the company reported a miss on new patient starts on January 8, according to the lawsuit. The allegations are unproven.
Beta Bionics shares traded at $18.11 in Wednesday trading as of 3:06 p.m. ET, down 2.79% from the prior close of $18.63 (market data). Market capitalization was $1.0 billion.
What to watch
The deadline for investors to ask to be appointed lead plaintiff in Holtzman v. Beta Bionics, pending in federal court in California, is November 3.
The November 3 lead-plaintiff deadline is the next scheduled step in the case.
Sources
- SCHEDULE 13G — T. Rowe Price Associates, Inc. re: BETA BIONICS INC (BBNX) — SEC EDGAR
- Kaplan Fox Announces a Securities Class Action Filed Against Beta Bionics, Inc. (NASDAQ: BBNX) - Lead Plaintiff Deadline is November 3, 2026 - The Globe and Mail — theglobeandmail.com
- BBNX Investor Reminder: BFA Law Reminds Beta Bionics Investors that Lost Money when Stock Dropped 37% of the Pending Securities Class Action and Upcoming Deadline — globenewswire.com
- Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance — prnewswire.com
- Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm — globenewswire.com
- Beta Bionics, Inc. Notice of November 3, 2026 Application — globenewswire.com
